1. Mitogen-activated protein kinase signalling and ERK1/2 bistability in asthma;Alam;Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology,2011
2. Efficacy of a covalent ERK1/2 inhibitor, CC-90003, in KRAS-mutant cancer models reveals novel mechanisms of response and resistance;Aronchik;Molecular Cancer Research: MCR,2019
3. A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation;Arvind;International Journal of Oncology,2005
4. Dabrafenib in combination with trametinib for the treatment of metastatic melanoma;Awad;Expert Review of Clinical Pharmacology,2015
5. Tumour cell survival signalling by the ERK1/2 pathway;Balmanno;Cell Death and Differentiation,2009